Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05093517 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
A Early Phase 1 study of Type 2 Diabetes and Insulin Sensitivity, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT05093517 is a Early Phase 1 study of Type 2 Diabetes and Insulin Sensitivity that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 4 participants, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05093517, a Early Phase 1 study of Type 2 Diabetes and Insulin Sensitivity, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
With REMD's glucagon receptor antagonist, the study team propose to provide a comprehensive examination of the effect of elevated plasma glucagon concentrations in Type 2 Diabetes Mellitus (T2D) patients on: (i) glucose tolerance; (ii) insulin sensitivity in liver, muscle, and adipocytes; (iii) beta cell function; (iv) adipocyte inflammation.
Conditions Studied
Interventions
- DRUG REMD-477
- DRUG Placebo Subcutaneous injection
Study Locations (1)
Texas
- Texas Diabetes Institute - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-11-10 |
| Est. Completion | 2022-03-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05093517
The ClinicalTrials.gov registry entry for NCT05093517 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (100% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which REMD-477 is the first listed.
NCT05093517 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05093517 about?
NCT05093517 is a clinical study titled "Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM". With REMD's glucagon receptor antagonist, the study team propose to provide a comprehensive examination of the effect of elevated plasma glucagon concentrations in Type 2 Diabetes Mellitus (T2D) patients on: (i) glucose tolerance; (ii) insulin sensitivity in liver, muscle, and adipocytes; (iii) bet...
What is the current status of trial NCT05093517?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2021-11-10. Estimated completion is 2022-03-16.
What conditions does trial NCT05093517 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Insulin Sensitivity, Glucose Tolerance Impaired.
What interventions are being tested in trial NCT05093517?
The interventions under investigation include: REMD-477 (DRUG), Placebo Subcutaneous injection (DRUG).
Who is sponsoring clinical trial NCT05093517?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05093517 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
-
SGLT2i, Hepatic Glucose Production, and SNS
RECRUITING · Early Phase 1
-
Precision Dosing of Metformin in Youth With T2D
RECRUITING · Early Phase 1
-
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
RECRUITING · Early Phase 1
-
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
RECRUITING · Early Phase 1
-
Antioxidant Treatment of Type 2 Diabetes
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.